Real-life use of ropeg-interferon α2b in polycythemia vera: patient selection and clinical outcomes
Real-life use of ropeg-interferon α2b in polycythemia vera: patient selection and clinical outcomes
About this item
Full title
Author / Creator
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Journal title
Language
English
Formats
Publication information
Publisher
Berlin/Heidelberg: Springer Berlin Heidelberg
Subjects
More information
Scope and Contents
Contents
Ropeginterferon-alfa2b (ropegIFNα2b) is a long-acting IFN formulation with broad FDA/EMA approval as a therapy of polycythemia vera (PV) with no symptomatic splenomegaly. There is currently lack of information on the real-world patient selection, including the impact of local reimbursement policies, and drug management, particularly: type/timing of...
Alternative Titles
Full title
Real-life use of ropeg-interferon α2b in polycythemia vera: patient selection and clinical outcomes
Authors, Artists and Contributors
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11224071
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_11224071
Other Identifiers
ISSN
0939-5555,1432-0584
E-ISSN
1432-0584
DOI
10.1007/s00277-024-05809-6
